Obizur (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 288 | Autoimmune acquired coagulation factor deficiency [Autoimmune Hemorrhaphilia XIII (~Mar 2017)] | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03199794 (ClinicalTrials.gov) | December 14, 2016 | 23/6/2017 | Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice | Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice | Acquired Hemophilia A | Biological: OBIZUR | Baxalta now part of Shire | Baxalta Innovations GmbH, now part of Shire | Recruiting | 18 Years | N/A | All | 50 | United States;Austria;France;Germany;Italy;Netherlands;United Kingdom | |
| 2 | NCT02610127 (ClinicalTrials.gov) | December 30, 2015 | 29/10/2015 | Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A | Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A | Acquired Hemophilia A | Biological: OBIZUR | Baxalta now part of Shire | Baxalta Innovations GmbH, now part of Shire | Completed | 18 Years | N/A | All | 53 | United States |